Type 2 diabetes is a condition where the body becomes resistant to insulin and, over time, the pancreas struggles to keep up. Blood sugar rises. Without treatment, this damages blood vessels, nerves, kidneys, and eyes. Tirzepatide addresses the underlying biology in several ways at once, which is why it produces strong reductions in HbA1c in clinical trials.

How Mounjaro Helps Type 2 Diabetes

The medication works on the gut, pancreas, and brain together.

It restores the meal time insulin response

Tirzepatide stimulates the pancreas to release insulin specifically when blood glucose is up. This restores the natural post meal insulin rise that is often blunted in type 2 diabetes.

It reduces glucagon

Glucagon is a hormone that raises blood sugar by telling the liver to produce glucose. In type 2 diabetes, glucagon is often inappropriately elevated. Tirzepatide brings it down, particularly after meals.

It slows gastric emptying

Food enters the small intestine more slowly, so glucose absorption is more gradual and the post meal glucose spike is blunted.

It reduces appetite and supports weight loss

Most people with type 2 diabetes carry excess weight. Weight loss directly improves insulin sensitivity and glucose control. Mounjaro produces both effects together.

What The Trials Showed

The SURPASS series of trials studied tirzepatide in type 2 diabetes against several comparators including placebo, insulin, dulaglutide (another GLP-1 medication), and semaglutide.

At maximum doses (15 mg) in adequately controlled adherence:

  • HbA1c reductions of around 2.0 to 2.4 percentage points from baseline
  • Substantially more people achieving HbA1c below 7.0 percent than on comparators
  • Many achieving HbA1c below 5.7 percent (the normal range)
  • Significant additional weight reduction

This is meaningful. A two percentage point HbA1c reduction is what older medications collectively achieved across multiple drugs added in sequence.

Talk To A Doctor About Your Diabetes

An online consultation reviews your current regimen and works out whether Mounjaro fits and how to integrate it safely.

Start Consultation

Where Mounjaro Sits In Diabetes Treatment

South African and international diabetes guidelines have evolved as evidence for GLP-1 and GIP/GLP-1 medications has grown. The general pattern is:

First line

Metformin remains first line for most people newly diagnosed with type 2 diabetes. Cheap, effective, well tolerated by most.

Second line and beyond

If HbA1c remains above target despite metformin, the choice of next medication depends on the individual. GLP-1 and GIP/GLP-1 medications (including Mounjaro), SGLT2 inhibitors, sulfonylureas, DPP4 inhibitors, and insulin are all options.

When Mounjaro becomes the favoured choice

  • HbA1c is significantly elevated and large reductions are needed
  • The person also needs significant weight reduction
  • There is cardiovascular disease (GLP-1 medications have cardiovascular benefit)
  • Previous medications have not been tolerated

Combining With Other Diabetes Medications

Tirzepatide can be used as monotherapy or combined with most other diabetes medications. A few specifics:

  • Metformin. Generally continued. The combination is common and well studied.
  • SGLT2 inhibitors (empagliflozin, dapagliflozin). Often continued, particularly in people with cardiovascular or kidney disease.
  • Sulfonylureas (glimepiride, gliclazide). Often reduced or stopped as Mounjaro takes effect, to avoid hypoglycaemia.
  • Insulin. Often reduced as Mounjaro takes effect. Sudden reduction without medical guidance can cause unstable glucose, so this needs the treating doctor's input.
  • DPP4 inhibitors (sitagliptin, linagliptin). Usually stopped when starting Mounjaro since they work on the same general pathway and the combination is not useful.
Always coordinate with your doctor Adjusting diabetes medication is something the treating doctor handles based on your current HbA1c, blood sugar logs, and how you respond to Mounjaro. Do not stop or change other diabetes medications without medical guidance.

What To Expect Starting Mounjaro For Diabetes

The titration is the same as for weight management. Start at 2.5 mg weekly for the first four weeks. Step up by 2.5 mg every four weeks until the target therapeutic dose is reached. For diabetes the typical target is 5 mg, 10 mg, or 15 mg depending on how much HbA1c reduction is needed.

Side effects, mostly gastrointestinal, are the same. Hypoglycaemia is uncommon unless you are also on insulin or a sulfonylurea, in which case dose adjustment of those is usually needed.

Diabetes Specific Cautions

  • Mounjaro is for type 2 diabetes only. It is not indicated for type 1 diabetes.
  • Diabetic retinopathy can occasionally worsen rapidly during fast glucose improvement. If you have known retinopathy, this should be flagged before starting.
  • Pancreatitis risk needs to be considered if you have a previous history.
  • Kidney function should be checked before and during treatment.

Related Reading

Frequently Asked

Sometimes. It depends on the current regimen and how well controlled the diabetes is. Some people add Mounjaro to existing oral medications. Others adjust or stop certain medications as Mounjaro takes effect. This is something the treating doctor decides.

Yes, in some cases. Combination requires careful insulin dose adjustment because Mounjaro improves glucose control, which can mean less insulin is needed and the risk of hypoglycaemia increases if insulin is not reduced.

On its own, no. Mounjaro stimulates insulin release in a glucose dependent way, meaning it only acts when blood sugar is up. The risk of hypoglycaemia comes when combined with insulin or sulfonylureas, which can lower blood sugar independently.

Reductions are usually visible within the first three months and continue to improve as the dose is titrated up. Clinical trial reductions in HbA1c at maximum doses are around 2 to 2.4 percentage points.